- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT00380289
Early Metabolic Changes With Thiazide or Beta Blocker Therapy for Essential Hypertension
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
We will be comparing the two most commonly used drugs to treat hypertension, atenolol and bendrofluazide, in patients for whom the drugs (and the doses to be used) are licenced.
We propose an initial open label pilot study of 10-12 patients to confirm final doses to be tested, the duration of therapy for optimum timing of the OGTT and tolerability of doses selected. The pilot study will also be used to confirm sample size calculations for the main study.The protocol for the pilot study will be identical to the main study, but there will not be a placebo phase and the treatment will not be blinded.
The main study will be double-blind, placebo controlled, cross-over study, of approximately 66 patients in which each patient receives in random order, 4 weeks treatment with either Bendrofluazide 5-10mg daily, Atenolol 50-100mg daily or combination of Bendrofluazide 2.5-5mg and Atenolol 25-50mg daily. There will be a forced titration from the lower to the higher dose stated half way through each dosing period. There will be a 1 month placebo wash-out between each dosing period.
At 0, 2 and 4 weeks of each treatment phase, patients will attend the Clinical Investigation Ward (CIW), fasting, for performance of an oral glucose tolerance test (OGTT). Blood will be drawn from an intravenous cannula, for the measurements of glucose and insulin at 0, 0.5, 1 and 2 hours.
Blood pressure will be measured at each study visit using an Omron machine. The patients will also be given a blood pressure machine to take home and will be asked to measure and record their blood pressure at least twice per week. If their blood pressure is under 110/70mmhg or over 160/110mmHg at any time or if the patient has symptoms e.g. headache or dizziness, the patient will be asked to contact study staff. If the blood pressure remains over 160/110 for two measurements, then another antihypertensive therapy may be commenced, or the patient withdrawn from the study. If blood pressure is < 110/70 mmHg with symptoms then a decision may be made to terminate their participation in the study.
Type d'étude
Inscription
Phase
- N'est pas applicable
Contacts et emplacements
Coordonnées de l'étude
- Nom: Professor MJ Brown, MA MSC MD FRCP
- Numéro de téléphone: 01223 762577 (UK)
- E-mail: mjb14@medschl.cam.ac.uk
Sauvegarde des contacts de l'étude
- Nom: Dr A Stears, MBBS BSc MRCP
- Numéro de téléphone: 01223 586865 (UK)
- E-mail: as659@medschl.cam.ac.uk
Lieux d'étude
-
-
-
Cambridge, Royaume-Uni, CB2 2QQ
- Recrutement
- Clinical Pharmacology Unit, Box 110, Level 3 ACCI, Addenbrookes Hospital
-
Contact:
- Mrs M Watts
- Numéro de téléphone: 01223 586865
- E-mail: mw363@medschl.cam.ac.uk
-
Contact:
- Dr A Stears, MBBS BSc MRCP
- Numéro de téléphone: 01223 586878
- E-mail: as659@medschl.cam.ac.uk
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Volunteers will be aged 18-75 years.
Hypertension- either
- untreated, BP 140-170/90-110
- treated for over 1 month with drugs other than beta blockers or diuretic and BP>140/85
- treated for over 1 month with drugs other than beta blockers or diuretic and BP<140/85 and patient willing to change medication for eight months.
Exclusion criteria:
- Any patient already taking thiazide diuretics or beta blockers in whom these drugs cannot be switched to alternative drugs with similar or better blood pressure control.
- Any patient who is intolerant of these medications will be excluded from the study.
- Patients with gout, asthma or any other contraindications to the study drugs will be excluded.
- Women of child bearing age not using contraception.
- Volunteers with heart failure, liver failure, renal failure, terminal illnesses (e.g. cancer)
- Volunteers not able to give informed consent
- Patients with diabetes
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation croisée
- Masquage: Double
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
---|
Can the oral glucose tolerance test detect changes after 4 weeks treatment with thiazide diuretics or beta blockers or combination of the two?
|
Mesures de résultats secondaires
Mesure des résultats |
---|
Do patients show a similar change in glucose tolerance after thiazide or beta blocker therapy?
|
Does the combination of drugs cause a greater reduction in glucose tolerance than expected from the response to each drug taken alone?
|
Collaborateurs et enquêteurs
Parrainer
Collaborateurs
Les enquêteurs
- Chercheur principal: Professor MJ Brown, MA MSC MD FRCP, Addenbrookes Hosptal NHS Trust/ University of Cambridge
Publications et liens utiles
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Estimation)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Estimation)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- OGTT1
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .
Essais cliniques sur L'hypertension artérielle essentielle
-
National Taiwan University Hospital Hsin-Chu BranchRecrutementHypertension Essentielle | Hypertension, masquéTaïwan
-
University of Alabama at BirminghamTroy UniversityComplétéHypertension | Hypertension, résistante à la thérapie conventionnelle | Hypertension non contrôlée | Hypertension, blouse blancheÉtats-Unis
-
Vanderbilt University Medical CenterJohns Hopkins UniversityComplétéHypertension artérielle pulmonaire | Hypertension artérielle pulmonaire idiopathique | Hypertension artérielle pulmonaire associée | Hypertension artérielle pulmonaire héréditaireÉtats-Unis
-
Centre Chirurgical Marie LannelongueInconnueHypertension pulmonaire thromboembolique chronique et hypertension artérielle pulmonaireFrance
-
Amsterdam UMC, location VUmcZonMw: The Netherlands Organisation for Health Research and DevelopmentInconnue
-
Assistance Publique - Hôpitaux de ParisActif, ne recrute pasHypertension portale non cirrhotique intrahépatiqueFrance
-
University of Kansas Medical CenterRecrutementHypertension artérielle pulmonaire | Hypertension pulmonaire | Hypertension pulmonaire thromboembolique chronique | Hypertension pulmonaire due à une cardiopathie gauche | Hypertension pulmonaire, primaire, 4 | Hypertension pulmonaire, primaire, 2 | Hypertension pulmonaire, primaire, 3 | Hypertension... et d'autres conditionsÉtats-Unis
-
AstraZenecaComplétéHypertension artérielle (hypertension).
-
Sheffield Teaching Hospitals NHS Foundation TrustUniversity of SheffieldComplétéHypertension artérielle pulmonaire idiopathique | Hypertension pulmonaire thromboembolique chroniqueRoyaume-Uni
-
BayerComplété